A COST-EFFECTIVENESS ANALYSIS OF PASIREOTIDE LONG-ACTING COMPARED TO CONTINUED USE OF A FIRST-LINE SOMATOSTATIN ANTAGONIST FOR THE TREATMENT OF ACROMEGALY IN SWEDEN
Author(s)
Carlqvist P, Wilen-Koort A
Novartis Sweden, Täby, Sweden
OBJECTIVES:
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PSY93
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Rare and Orphan Diseases
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now